Clinical Trials Logo

Clinical Trial Summary

Partial splenectomy or total splenectomy are the two surgical treatment of non-malignant hemoglobinoptahie. The aim of this treatment is to decrease transfusion. The main risk is infectious in total splenectomy, that's why partial splenectomy was suggest. But the efficiency of partial splenectomy decrease over time and a totalisation could be mandatory.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05184647
Study type Observational
Source University Hospital, Montpellier
Contact Nicolas KALFA, MD
Phone 00334 67 33 87 84
Email n-kalfa@chu-montpellier.fr
Status Not yet recruiting
Phase
Start date January 16, 2022
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Not yet recruiting NCT06025487 - Meningococcal B Vaccine in Patients With Asplenia Phase 2
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy(ESAWAAPT) Phase 4
Recruiting NCT05325424 - The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients N/A
Recruiting NCT05339269 - The Effect of Laparoscopic Splenectomy on the Immune Function for Cirrhosis Patients N/A
Recruiting NCT05325437 - The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients N/A
Recruiting NCT05338294 - The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients N/A
Completed NCT03571399 - A Nationwide Italian Survey on Asplenia
Completed NCT04056507 - Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura